Hepatic Encephalopathy clinical trials at UCLA

1 in progress, 0 open to eligible people

Showing trials for

  • Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

    Sorry, in progress, not accepting new patients

    Study RNLC3131 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.

    Los Angeles, California and other locations

Last updated: